Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (41)
  • Open Access

    PROCEEDINGS

    Research on the Synergistic Mechanism of Photothermal-Chemotherapy-Immunotherapy of Multi-Functional Nanoparticles Against Gastric Cancer

    Erdong Shen1, Ting Pan1, Pan Guo1, Ke Chen1, Rui Xu1, Mei Yang1, Dahe Zhan1, Fang Fang1, Qinghui Wu1,*, Jianbing Hu1,*

    The International Conference on Computational & Experimental Engineering and Sciences, Vol.30, No.4, pp. 1-3, 2024, DOI:10.32604/icces.2024.012772

    Abstract Objective
    This study investigates the synergistic effects of a novel multifunctional nanoparticle on gastric cancer treatment through photothermal therapy, chemotherapy, and immunotherapy.

    Method
    Synthesize hollow mesoporous Prussian blue nanoparticles and load them with luteolin. Use exosomes to encapsulate the nanoparticles and modify the surface of the targeted peptide GX1. Detect the morphology of nanoparticles using a nanoparticle size analyzer and transmission electron microscopy. Use Coomassie Brilliant Blue to detect the effect of extracellular vesicle encapsulation. Detect the thermal conversion efficiency of nanoparticles under specific laser irradiation through infrared and ultraviolet spectroscopy, as well as the release rate… More >

  • Open Access

    ARTICLE

    Exploring the effects of taurolidine on tumor weight and microvessel density in a murine model of osteosarcoma

    LISANNE K.A. NEIJENHUIS1,2,3,#, LEUTA L. NAUMANN4,#, SONIA A.M. FERKEL1, SAMUEL J.S. RUBIN1, STEPHAN ROGALLA1,*

    Oncology Research, Vol.32, No.7, pp. 1163-1172, 2024, DOI:10.32604/or.2024.050907 - 20 June 2024

    Abstract Background: Osteosarcoma is the most common malignant primary bone tumor. The prognosis for patients with disseminated disease remains very poor despite recent advancements in chemotherapy. Moreover, current treatment regimens bear a significant risk of serious side effects. Thus, there is an unmet clinical need for effective therapies with improved safety profiles. Taurolidine is an antibacterial agent that has been shown to induce cell death in different types of cancer cell lines. Methods: In this study, we examined both the antineoplastic and antiangiogenic effects of taurolidine in animal models of osteosarcoma. K7M2 murine osteosarcoma cells were… More >

  • Open Access

    ARTICLE

    Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of GNAL in glioma

    ZHEN LIU1,#, LIANGWANG YANG2,#, ZHENGXING XIE1, HUI YU3, TIANYI GU3, DAOMING SHI4, NING CAI1,*, SHENGHUA ZHUO2,*

    Oncology Research, Vol.32, No.5, pp. 965-981, 2024, DOI:10.32604/or.2024.045769 - 23 April 2024

    Abstract Clinical data indicates that glioma patients have poor treatment outcomes and clinical prognosis. The role of olfactory signaling pathway-related genes (OSPRGs) in glioma has not been fully elucidated. In this study, we aimed to investigate the role and relationship between OSPRGs and glioma. Univariate and multivariate Cox regression analyses were performed to assess the relationship between OSPRGs and the overall survival of glioma based on public cohorts, and the target gene (G Protein Subunit Alpha L, GNAL) was screened. The association of GNAL expression with clinicopathological characteristics, gene mutation landscape, tumor immune microenvironment (TIME), deoxyribonucleic acid… More >

  • Open Access

    REVIEW

    Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review

    EFFAT ALEMZADEH1, LEILA ALLAHQOLI2, AFROOZ MAZIDIMORADI3, ESMAT ALEMZADEH1,4, FAHIMEH GHASEMI4,5, HAMID SALEHINIYA6, IBRAHIM ALKATOUT7,*

    Oncology Research, Vol.32, No.5, pp. 831-847, 2024, DOI:10.32604/or.2024.031006 - 23 April 2024

    Abstract Ovarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for maintenance therapy. However, resistance to these new drugs has emerged. Therefore, understanding the mechanisms of DR and exploring new approaches to overcome More >

  • Open Access

    ARTICLE

    Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects

    QIAN HU, MENGYAO WANG, JINJIN WANG, YALI TAO, TING NIU*

    Oncology Research, Vol.32, No.4, pp. 753-768, 2024, DOI:10.32604/or.2023.043647 - 20 March 2024

    Abstract Multiple myeloma (MM) is a hematologic malignancy notorious for its high relapse rate and development of drug resistance, in which cell adhesion-mediated drug resistance plays a critical role. This study integrated four RNA sequencing datasets (CoMMpass, GSE136337, GSE9782, and GSE2658) and focused on analyzing 1706 adhesion-related genes. Rigorous univariate Cox regression analysis identified 18 key prognosis-related genes, including KIF14, TROAP, FLNA, MSN, LGALS1, PECAM1, and ALCAM, which demonstrated the strongest associations with poor overall survival (OS) in MM patients. To comprehensively evaluate the impact of cell adhesion on MM prognosis, an adhesion-related risk score (ARRS)… More >

  • Open Access

    ARTICLE

    Identifying and validating MMP family members (MMP2, MMP9, MMP12, and MMP16) as therapeutic targets and biomarkers in kidney renal clear cell carcinoma (KIRC)

    KUNLUN LI1, DANDAN LI2, BARBOD HAFEZ3,*, MOUNIR M. SALEM BEKHIT4, YOUSEF A. BIN JARDAN4, FARS KAED ALANAZI4, EHAB I. TAHA4, SAYED H. AUDA4, FAIQAH RAMZAN5,*, MUHAMMAD JAMIL6

    Oncology Research, Vol.32, No.4, pp. 737-752, 2024, DOI:10.32604/or.2023.042925 - 20 March 2024

    Abstract Kidney Renal Clear Cell Carcinoma (KIRC) is a malignant tumor that carries a substantial risk of morbidity and mortality. The MMP family assumes a crucial role in tumor invasion and metastasis. This study aimed to uncover the mechanistic relevance of the MMP gene family as a therapeutic target and diagnostic biomarker in Kidney Renal Clear Cell Carcinoma (KIRC) through a comprehensive approach encompassing both computational and molecular analyses. STRING, Cytoscape, UALCAN, GEPIA, OncoDB, HPA, cBioPortal, GSEA, TIMER, ENCORI, DrugBank, targeted bisulfite sequencing (bisulfite-seq), conventional PCR, Sanger sequencing, and RT-qPCR based analyses were used in the… More >

  • Open Access

    ARTICLE

    Transient receptor potential channels as predictive marker and potential indicator of chemoresistance in colon cancer

    WEI HU1,#, THOMAS WARTMANN2,#, MARCO STRECKER2, ARISTOTELIS PERRAKIS2, ROLAND CRONER2, ARPAD SZALLASI3, WENJIE SHI2,*, ULF D. KAHLERT2,*

    Oncology Research, Vol.32, No.1, pp. 227-239, 2024, DOI:10.32604/or.2023.043053 - 15 November 2023

    Abstract Transient receptor potential (TRP) channels are strongly associated with colon cancer development and progression. This study leveraged a multivariate Cox regression model on publicly available datasets to construct a TRP channels-associated gene signature, with further validation of signature in real world samples from our hospital treated patient samples. Kaplan-Meier (K-M) survival analysis and receiver operating characteristic (ROC) curves were employed to evaluate this gene signature’s predictive accuracy and robustness in both training and testing cohorts, respectively. Additionally, the study utilized the CIBERSORT algorithm and single-sample gene set enrichment analysis to explore the signature’s immune infiltration… More > Graphic Abstract

    Transient receptor potential channels as predictive marker and potential indicator of chemoresistance in colon cancer

  • Open Access

    ARTICLE

    Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer

    SUNG HEE LIM1,#, HEE JIN CHO1,2,3,#, KYOUNG-MEE KIM4, HO YEONG LIM1, WON KI KANG1, JEEYUN LEE1, YOUNG SUK PARK1, HEE CHEOL KIM5,*, SEUNG TAE KIM1,*

    Oncology Research, Vol.31, No.6, pp. 855-866, 2023, DOI:10.32604/or.2023.030374 - 15 September 2023

    Abstract Background: Although bevacizumab is an important treatment for metastatic colorectal cancer (CRC), not all patients with CRC benefit from it; in unselected patient populations, only modest survival benefits have been reported. Methods: We evaluated clinical outcomes in 110 patients using comprehensive molecular characterization to identify biomarkers for a response to bevacizumab-containing treatment. The molecular analysis comprised whole-exome sequencing, ribonucleic acid sequencing, and a methylation array on patient tissues. Results: Genomic and molecular characterization was successfully conducted in 103 patients. Six of 103 CRC samples were hypermutated, and none of the non-hypermutant tumors were microsatellite unstable. Among… More >

  • Open Access

    ARTICLE

    The DMRTA1-SOX2 positive feedback loop promotes progression and chemotherapy resistance of esophageal squamous cell carcinoma

    RUI ZHANG1,2,#, PENG ZHOU1,3,#, XIA OU4, PEIZHU ZHAO2, XIJING GUO2, MIAN XI5,*, CHEN QING1,*

    Oncology Research, Vol.31, No.6, pp. 887-897, 2023, DOI:10.32604/or.2023.030184 - 15 September 2023

    Abstract Esophageal squamous cell carcinoma (ESCC) is among the most prevalent causes of cancer-related death in patients worldwide. Resistance to immunotherapy and chemotherapy results in worse survival outcomes in ESCC. It is urgent to explore the underlying molecular mechanism of immune evasion and chemoresistance in ESCC. Here, we conducted RNA-sequencing analysis in ten ESCC tissues from cisplatin-based neoadjuvant chemotherapy patients. We found that DMRTA1 was extremely upregulated in the non-pathologic complete response (non-pCR) group. The proliferation rate of esophageal squamous carcinoma cells was markedly decreased after knockdown of DMRTA1 expression, which could increase cisplatin sensitivity in More >

  • Open Access

    ARTICLE

    Deciphering key genes involved in cisplatin resistance in kidney renal clear cell carcinoma through a combined in silico and in vitro approach

    MUNEEBA MALIK1, MAMOONA MAQBOOL2, TOOBA NISAR3, TAZEEM AKHTER4, JAVED AHMED UJAN5,6, ALANOOD S. ALGARNI7, FAKHRIA A. AL JOUFI8, SULTAN SHAFI K. ALANAZI9, MOHAMMAD HADI ALMOTARED10, MOUNIR M. SALEM BEKHIT11, MUHAMMAD JAMIL12,*

    Oncology Research, Vol.31, No.6, pp. 899-916, 2023, DOI:10.32604/or.2023.030760 - 15 September 2023

    Abstract The low survival rate of Kidney renal clear cell carcinoma (KIRC) patients is largely attributed to cisplatin resistance. Rather than focusing solely on individual proteins, exploring protein-protein interactions could offer greater insight into drug resistance. To this end, a series of in silico and in vitro experiments were conducted to identify hub genes in the intricate network of cisplatin resistance-related genes in KIRC chemotherapy. The genes involved in cisplatin resistance across KIRC were retrieved from the National Center for Biotechnology Information (NCBI) database using search terms as “Kidney renal clear cell carcinoma” and “Cisplatin resistance”. The genes… More >

Displaying 1-10 on page 1 of 41. Per Page